Press Release 24 October 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or “Sativa Investments” or “the Company” or “the Group”)
Change in Board responsibilities
Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, announces that Mark Blower, currently an Executive Director of the Company, is moving to a non-Executive Director role with immediate effect.
– Ends –
For further information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
Notes to Editors
Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted. Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa acquires can either be public or private.
Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.
The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.
Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.
The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: www.sativagroup.co.uk